Scarica l'app Stockscreener
0.9729
2.71%
-0.0271
Dopo l'orario di chiusura:
.99
0.0171
+1.76%
Precedente Chiudi:
$1.00
Aprire:
$1.01
Volume 24 ore:
1.75M
Relative Volume:
1.07
Capitalizzazione di mercato:
$112.20M
Reddito:
$13.45M
Utile/perdita netta:
$-178.23M
Rapporto P/E:
-0.5896
EPS:
-1.65
Flusso di cassa netto:
$-132.53M
1 W Prestazione:
-9.92%
1M Prestazione:
-8.22%
6M Prestazione:
+2.41%
1 anno Prestazione:
-72.36%
Intervallo 1D:
$0.95
$1.015
Intervallo di 1 settimana:
$0.95
$1.10
Portata 52W:
$0.6611
$4.20
Fate Therapeutics Inc Stock (FATE) Company Profile
Nome
Fate Therapeutics Inc
Settore
Industria
Telefono
858.875.1803
Indirizzo
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Confronta FATE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
0.9729 | 118.79M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-01-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Downgrade | Stifel | Buy → Hold |
| 2023-01-06 | Downgrade | Truist | Buy → Hold |
| 2023-01-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Iniziato | Goldman | Sell |
| 2022-11-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-18 | Ripresa | Wells Fargo | Overweight |
| 2022-07-28 | Iniziato | Needham | Hold |
| 2022-07-11 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-11 | Ripresa | BMO Capital Markets | Market Perform |
| 2021-12-15 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-11-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-26 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Jefferies | Buy |
| 2021-02-26 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-02-11 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-27 | Ripresa | H.C. Wainwright | Neutral |
| 2020-05-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-09 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Reiterato | Mizuho | Buy |
| 2019-12-09 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-06-07 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2019-03-28 | Iniziato | SVB Leerink | Outperform |
| 2019-01-03 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Iniziato | Jefferies | Buy |
| 2018-08-01 | Iniziato | Citigroup | Buy |
| 2018-03-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mostra tutto
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Is Fate Therapeutics Inc. stock entering bullish territoryTrade Exit Summary & Weekly High Potential Alerts - Newser
Institutional scanner results for Fate Therapeutics Inc.2025 Technical Overview & Stepwise Swing Trade Plans - Newser
Does Fate Therapeutics Inc. align with a passive investing strategyInflation Watch & Consistent Income Trade Recommendations - khodrobank.com
Heatmap analysis for Fate Therapeutics Inc. and competitorsJuly 2025 WrapUp & Fast Gain Stock Tips - Newser
Using data models to predict Fate Therapeutics Inc. stock movementJuly 2025 Macro Moves & Weekly High Return Stock Forecasts - Newser
Volume spikes in Fate Therapeutics Inc. stock – what they meanJuly 2025 Rallies & Free Safe Entry Trade Signal Reports - Newser
What MACD and RSI say about Fate Therapeutics Inc.Quarterly Profit Report & AI Powered Market Trend Analysis - Newser
Can volume confirm reversal in Fate Therapeutics Inc.Portfolio Value Summary & Growth Oriented Trade Recommendations - Newser
Why Fate Therapeutics Inc. stock attracts strong analyst attentionTrade Analysis Summary & Short-Term Trading Alerts - Newser
Will Fate Therapeutics Inc. bounce back from current supportProduct Launch & Accurate Buy Signal Alerts - Newser
Published on: 2025-09-03 09:36:15 - Newser
Has Fate Therapeutics Inc. found a price floorWall Street Watch & Risk Managed Trade Strategies - Newser
Will Fate Therapeutics Inc. stock hit new highs in YEARJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - khodrobank.com
Chart overlay techniques for tracking Fate Therapeutics Inc.2025 Technical Patterns & Entry and Exit Point Strategies - Newser
Detecting support and resistance levels for Fate Therapeutics Inc.July 2025 Snapshot & Daily Entry Point Alerts - Newser
Building trade automation scripts for Fate Therapeutics Inc.M&A Rumor & Low Risk Entry Point Tips - Newser
Backtesting results for Fate Therapeutics Inc. trading strategiesMarket Trend Review & Smart Allocation Stock Reports - Newser
Market reaction to Fate Therapeutics Inc.’s recent newsJuly 2025 Recap & High Accuracy Investment Entry Signals - Newser
Visual trend scoring systems applied to Fate Therapeutics Inc.July 2025 Levels & Daily Oversold Bounce Ideas - Newser
Is Fate Therapeutics Inc. trending in predictive chart modelsTake Profit & Verified Momentum Watchlists - Newser
Is Abeona Therapeutics Inc. attractive at current valuation2025 Macro Impact & Consistent Return Investment Signals - خودرو بانک
What is Fate Therapeutics Inc. s 5 year growth outlookTrade Volume Report & Weekly Breakout Stock Alerts - khodrobank.com
Is Fate Therapeutics Inc. forming a bottoming baseJuly 2025 Sector Moves & Stock Portfolio Risk Management - Newser
Fate Therapeutics Inc. Crosses 200 Day MA — Signal or Noise getLinesFromResByArray error: size == 0 - kangso.co.kr
Will Fate Therapeutics Inc. stock go up soon2025 Volume Leaders & Technical Analysis for Trade Confirmation - Newser
Comparing Fate Therapeutics Inc. in custom built stock radarsRisk Management & Weekly Top Performers Watchlists - Newser
What is Fate Therapeutics Inc.’s valuation compared to sectorMarket Activity Report & Fast Entry Momentum Alerts - khodrobank.com
What are Fate Therapeutics Inc.’s recent SEC filings showingTrade Analysis Summary & Community Verified Trade Signals - خودرو بانک
Published on: 2025-09-01 01:36:52 - Newser
Fate Therapeutics Inc. stock trend forecastEarnings Summary Report & Community Driven Trade Alerts - Newser
Understanding Fate Therapeutics Inc.’s price movementMarket Movement Recap & Real-Time Buy Zone Alerts - Newser
How to interpret RSI for Fate Therapeutics Inc. stockLong Setup & Advanced Technical Analysis Signals - Newser
Tick level data insight on Fate Therapeutics Inc. volatilityWeekly Trade Report & Low Risk Investment Opportunities - Newser
Fate Therapeutics Inc. stock momentum explainedPortfolio Gains Report & Consistent Income Trade Ideas - Newser
RSI Crosses Above 30 for Fate Therapeutics Inc. — Reversal in Sight2025 Key Lessons & Fast Gain Swing Alerts - beatles.ru
Can technical indicators confirm Fate Therapeutics Inc.’s reversalJuly 2025 PostEarnings & Daily Price Action Insights - Newser
What data driven models say about Fate Therapeutics Inc.’s futureWeekly Trade Review & Capital Efficient Trading Techniques - Newser
Fibonacci Levels Suggest Recovery for Fate Therapeutics Inc. getLinesFromResByArray error: size == 0 - thegnnews.com
Fate Therapeutics Inc Azioni (FATE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Fate Therapeutics Inc Azioni (FATE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Valamehr Bahram | President and CEO |
Aug 04 '25 |
Sale |
1.06 |
14,466 |
15,396 |
334,898 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):